Vitiligo: Not just an aesthetic disorder

Vitiligo is a chronic, acquired pigmentary disorder of the skin characterized by the loss of melanocytes and consequent development of well-demarcated depigmented patches. It is a relatively common condition, affecting approximately 0.5–2% of the world-wide population, irrespective of sex or ethnicity. The etiology is multifactorial and remains incompletely understood; autoimmune mechanisms with selective destruction of the melanocytes, plays a central role. Genetic predisposition, oxidative stress, and environmental triggers further contribute to disease onset and progression. Clinically, vitiligo presents as white macules and patches, most often localized on the face, hands, feet, and other sites of the body. The disorder is frequently associated with comorbid autoimmune diseases, such as autoimmune thyroiditis, type 1 diabetes mellitus, and alopecia areata. Diagnosis is primarily clinical, sometimes the exclusion of other causes of hypopigmentation can be a problem. Therapeutic strategies aim to stabilize disease activity and achieve repigmentation. Common approaches include topical antiinflammatory agents as corticosteroids and/or calcineurin inhibitors, and phototherapy with narrowband UVB. In selected cases, surgical methods with melanocyte transplantation may be considered. Recently, local Janus kinase (JAK) inhibitors have emerged as promising targeted therapies, offering new opportunities for effective disease control. Although vitiligo is not a direct threat to physical health, its cosmetic impact and psychosocial burden significantly affect quality of life. Consequently, a multidisciplinary approach with both dermatological treatment and psychological support is essential for comprehensive patient care.